BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.28 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 10:20PM GMT
Release Date Price: €112 (+0.90%)
Ziyi Chen
Goldman Sachs Group Inc., Research Division - Equity Analyst

Good afternoon. Thank you very much for joining this session. This is Ziyi Chen, China health care analyst at Goldman Sachs. Today, we have John Oyler, founder, CEO and Chairman of BeiGene with us, and also Howard Liang, CFO and Chief Strategy Officer, with us to talk about the recent updates on the BeiGene and overall strategy.

Questions & Answers

Ziyi Chen
Goldman Sachs Group Inc., Research Division - Equity Analyst

Probably start with some of the macro questions because BeiGene is now probably size $7 billion to $8 billion company. It's becoming a really sizable biotech company now. So when we talk about -- when we think of allocating our resources with multiple operation globally, so how are we going to spend the money smartly?

John V. Oyler
BeiGene, Ltd. - Co-Founder, Chairman & CEO

Sure. Maybe I can start. I think that one of the things you mentioned is BeiGene is a global company. To us, this is a global industry. You

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot